Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination, Versus PLD Alone, in Subjects With Platinum-Resistant Ovarian Cancer
Brief Summary: The objective of this study is to compare progression-free survival (PFS), based upon investigator assessment using Response Evaluation Criteria In Solid Tumors version 1.0 (RECIST 1.0) and clinical findings, in participants with platinum-resistant ovarian cancer who receive combination therapy with vintafolide and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) with that in subjects with platinum-resistant ovarian cancer who receive PLD alone.


Options:
A: Arm Label: Arm I (PLD, atezolizumab); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm II (PLD, bevacizumab, atezolizumab); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Biological: Bevacizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm III (PLD, bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab)
B: Arm Label: Standard treatment; Type: OTHER; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel + Bevacizumab + Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Rucaparib | Arm Label: Carboplatin + Paclitaxel + Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Rucaparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Standard treatment | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Carboplatin + Paclitaxel + Bevacizumab + Rucaparib, Carboplatin + Paclitaxel + Rucaparib
C: Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD
D: Arm Label: Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: Nintedanib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin (PLD), Drug: Topotecan, Drug: Carboplatin, Drug: Doxorubicin | Intervention Type: DRUG; Name: Nintedanib; Assigned to Arm(s): Nintedanib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin (PLD); Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Chemotherapy

Answer: C